FrancophonIA/ELRC3.0 huggingface dataset:
English: EVOTAZ should not be used in combination with another antiretroviral that requires pharmacokinetic enhancement (i.e., another protease inhibitor or elvitegravir) since dosing recommendations for such combinations have not been established and may result in decreased plasma concentrations of atazanavir and/or the other antiretroviral leading to loss of therapeutic effect and development of resistance.
Slovenian: Zdravila EVOTAZ se ne sme uporabljati v kombinaciji z drugimi protiretrovirusnimi zdravili, katerih farmakokinetiko je treba okrepiti (npr. drugi zaviralci proteaz ali elvitegravir), saj priporočila za odmerjanje takšnih kombinacij niso znana, pri sočasni uporabi pa se koncentracije atazanavirja in/ali drugih protiretrovirusnih zdravil v plazmi lahko zmanjšajo, kar lahko povzroči izgubo terapevtskega učinka in razvoj odpornosti.
English: Co-administration with antiretroviral medicinal products EVOTAZ is indicated for use with other antiretrovirals for the treatment of HIV-1 infection.
Slovenian: Sočasna uporaba z drugimi protiretrovirusnimi zdravili Uporaba zdravila EVOTAZ je indicirana skupaj z drugimi protiretrovirusnimi zdravili za zdravljenje okužbe z virusom HIV-1.
English: When co-administering with EVOTAZ, titrate the digoxin dose and monitor digoxin concentrations.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ je treba odmerek digoksina titrirati in nadzirati koncentracije digoksina.
English: In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection.
Slovenian: Poleg oportunističnih okužb pa se po začetku jemanja zdravil za zdravljenje okužbe z virusom HIV lahko pojavijo tudi avtoimunske bolezni (stanja, do katerih pride, ko imunski sistem napade zdravo telesno tkivo).
English: Didanosine (with food) Didanosine AUC ↓34% (↓40%
Slovenian: Didanozin (skupaj s hrano) Didanozin AUC ↓34% (↓40%
English: Studies in humans and in vitro studies using human liver microsomes have demonstrated that atazanavir is principally metabolised by CYP3A4 isozyme to oxygenated metabolites.
Slovenian: Študije, izvedene pri ljudeh, in študije in vitro na človeških jetrnih mikrosomih so pokazale, da se atazanavir v glavnem presnavlja z izoencimom CYP3A4 v oksigenirane presnovke.
English: Viruses were known to be susceptible to atazanavir, emtricitabine and tenofovir DF at baseline.
Slovenian: Virusi so bili v izhodišču znano dovzetni za atazanavir, emtricitabin in tenofovir DF.
English: Among the 19 patients, 1 developed the emtricitabine-associated resistance substitution M184V with no tenofovir or protease inhibitor associated resistance substitutions.
Slovenian: Od 19 bolnikov je 1 bolnik razvil z emtricitabinom povezano rezistenčno substitucijo M184V, brez s tenofovirjem ali z zaviralci proteaz povezanih rezistenčnih substitucij.
English: ANTIEPILEPTICS
Slovenian: ANTIEPILEPTIKI
English: Patients should be warned about these possible side effects when using PDE5 inhibitors for erectile dysfunction with EVOTAZ (see section 4.4).
Slovenian: Bolnike je treba opozoriti na te možne neželene učinke pri uporabi zaviralcev PDE5 za zdravljenje erektilne disfunkcije, če se jih uporablja skupaj z zdravilom EVOTAZ (glejte poglavje 4.4).
English: Patients receiving tenofovir disoproxil should be monitored for tenofovir-associated adverse reactions.
Slovenian: Bolnike, ki se zdravijo s dizoproksiltenofoviratom, je treba nadzirati glede neželenih učinkov, povezanih s tenofovirjem.
English: Other marked clinical laboratory abnormalities (Grade 3 or 4) reported in ≥ 2% of patients receiving regimens containing atazanavir and one or more NRTIs included: elevated creatine kinase (7%), elevated alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT) (5%), low neutrophils (5%), elevated aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) (3%), and elevated lipase (3%).
Slovenian: Druge izrazite laboratorijske nepravilnosti (stopnje 3 ali 4 ), o katerih so poročali pri ≥ 2 % bolnikov, ki so prejemali atazanavir in enega ali več NRTI-jev, so: zvišanje kreatin-kinaze (7 %), zvišanje alanin-aminotransferaze/serumske glutamat-piruvat-transaminaze (ALT/SGPT) (5%), zmanjšanje števila nevtrofilcev (5 %), zvišanje aspartat-aminotransferaze/serumske glutamat-oksalacetat-transaminaze (AST/SGOT) (3 %) in zvišanje lipaze (3 %).
English: Human experience of acute overdose with EVOTAZ is limited.
Slovenian: Izkušnje z akutnim prevelikim odmerjanjem zdravila EVOTAZ pri človeku so omejene.
English: Caution is also required during the first time of treatment if switching the pharmacoenhancer from ritonavir to cobicistat (see section 4.4).
Slovenian: Previdnost je tudi potrebna v primeru prve zamenjave ojačevalca farmakokinetike z ritonavirja na kobicistat (glejte poglavje 4.4).
English: In an ex vivo rabbit pharmacology study, isolated hearts were exposed to atazanavir, cobicistat, or atazanavir and cobicistat in combination.
Slovenian: V ex vivo farmakološki študiji pri kuncih so izolirana srca izpostavili atazanavirju, kobicistatu ali kombinaciji atazanavirja in kobicistata.
English: Metabolites are then excreted in the bile as either free or glucuronidated metabolites.
Slovenian: Presnovki se nato izločijo z žolčem kot prosti ali glukuronidirani presnovki.
English: Effects of co-administration of EVOTAZ on progestin and estrogen are unknown.
Slovenian: Učinki sočasne uporabe zdravila EVOTAZ na progestin in estrogen niso znani.
English: Very common (may affect more than 1 in 10 people) ocular icterus (presence of jaundice in the white part of the eyes, i.e. the eyes become yellow) nausea jaundice (when the skin and/or eyes become yellow)
Slovenian: Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov) očesni ikterus (zlatenica, ki se kaže kot rumeno obarvanje očesnih beločnic (oči postanejo rumene)) siljenje na bruhanje zlatenica (rumeno obarvanje kože in/ali oči)
English: Each bottle contains 30 film-coated tablets and a silica gel dessicant.
Slovenian: Ena plastenka vsebuje 30 filmsko obloženih tablet in silikagel kot sušilno sredstvo.
English: In a multiple-dose study in HIV-infected patients dosed with 400 mg of atazanavir once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen.
Slovenian: Pri bolnikih, okuženih z virusom HIV, ki so v študiji s ponavljajočim se odmerjanjem 12 tednov prejemali atazanavir v odmerku 400 mg enkrat na dan skupaj z lahkim obrokom, so atazanavir odkrili v cerebrospinalni tekočini in semenu.
English: The most frequently reported laboratory abnormality in paediatric patients receiving atazanavir was elevation of total bilirubin (≥ 2.6 times ULN, Grade 3-4) which occurred in 45% of patients.
Slovenian: Od laboratorijskih nepravilnosti so pri pediatričnih bolnikih, ki so prejemali atazanavir, najpogosteje poročali o zvišanju vrednosti celokupnega bilirubina (≥ 2,6-kratna ZMN, stopnja 3-4), in sicer pri 45 % bolnikov.
English: For patients who are taking tenofovir DF, it is not recommended to co-administer EVOTAZ with an H2-receptor antagonist.
Slovenian: Pri bolnikih, ki se zdravijo s tenofovirjem DF, zdravila EVOTAZ ni priporočljivo uporabljati skupaj z antagonistom histaminskih receptorjev H2.
English: Two minor metabolites of atazanavir in plasma have been characterised.
Slovenian: V plazmi so našli dva manj pomembna presnovka atazanavirja.
English: e Includes subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy,
Slovenian: e Vključuje bolnike, ki so bili izključeni zaradi razlogov, ki niso neželeni učinki, smrt ali pomanjkanje ali izguba učinkovitosti, npr. umik soglasja in izgubljeni za spremljanje.
English: Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions (see section 4.8).
Slovenian: Pri bolnikih s kroničnim hepatitisom B ali C, ki se zdravijo s kombiniranim protiretrovirusnim zdravljenjem, obstaja večje tveganje za pojav resnih in potencialno smrtnih neželenih učinkov za jetra (glejte poglavje 4.8).
English: An increase of > 3 x ULN in alanine aminotransferase or aspartate aminotransferase was recorded in 12.8% of subjects in the cobicistat-boosted group and 9.0% in the ritonavir-boosted group.
Slovenian: Povečanje vrednosti alanin-aminotransferaze ali aspartat-aminotransferaze za > 3 x ZMN so zabeležili pri 12,8 % bolnikov iz skupine okrepitve s kobicistatom in 9,0 % bolnikov iz skupine okrepitve z ritonavirjem.
English: Didanosine should be taken in the fasted state 2 hours after EVOTAZ taken with food.
Slovenian: Didanozin mora bolnik jemati na prazen želodec 2 uri po zdravilu EVOTAZ, ki ga vzame skupaj s hrano.
English: If overdose occurs with EVOTAZ, the patient must be monitored for evidence of toxicity.
Slovenian: V primeru prevelikega odmerjanja zdravila EVOTAZ je treba bolnika nadzirati glede pojava znakov toksičnosti.
English: Atazanavir is a weak to moderate inhibitor of CYP2C8.
Slovenian: Atazanavir je šibek do zmeren zaviralec CYP2C8.
English: Of these 692 patients, 613 (300 atazanavir with cobicistat and 313 atazanavir with ritonavir) and 496 (250 atazanavir with cobicistat and 246 atazanavir with ritonavir) received at least 48 and 144 weeks of treatment, respectively.
Slovenian: Od teh 692 bolnikov se je 613 bolnikov (300 atazanavir s kobicistatom in 313 atazanavir z ritonavirjem) zdravilo najmanj 48 tednov, 496 bolnikov (250 atazanavir s kobicistatom in 246 atazanavir z ritonavirjem) pa se je zdravilo najmanj 144 tednov.
English: An initial dose reduction of diltiazem by 50% should be considered, and electrocardiogram monitoring is recommended.
Slovenian: Razmisliti je treba o zmanjšanju začetnega odmerka diltiazema za 50 %.
English: High density polyethylene (HDPE) bottle with a child-resistant polypropylene closure.
Slovenian: Plastenka iz polietilena visoke gostote (HDPE), zaprta z za otroke varno polipropilensko zaporko.
English: When co-administered with tenofovir DF, it is recommended that EVOTAZ and tenofovir DF 300 mg be given together with food.
Slovenian: Pri sočasni uporabi tenofovirja DF je priporočljivo zdravilo EVOTAZ in tenofovir DF v odmerku 300 mg jemati skupaj s hrano.
English: A study of the pharmacokinetics of cobicistat was performed in non-HIV-1 infected subjects with severe renal impairment (estimated creatinine clearance below 30 ml/min).
Slovenian: Farmakokinetično študijo s kobicistatom so izvedli pri bolnikih brez okužbe z virusom HIV-1, ki so imeli hudo okvaro ledvic (ocenjeni kreatininski očistek manjši od 30 ml/min).
English: Plasma concentrations of these medicinal products may be increased when co-administered with EVOTAZ, resulting in reduced serum cortisol concentrations.
Slovenian: Plazemske koncentracije teh zdravil se lahko ob sočasnem dajanju zdravila EVOTAZ povečajo, kar povzroči zmanjšanje serumskih koncentracij kortizola.
English: Co-administration of EVOTAZ and rilpivirine can be used without dose adjustments, as the expected increase in rilpivirine concentrations is not considered clinically relevant.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ in rilpivirina odmerkov ni treba prilagajati, saj pričakovano povečanje koncentracij rilpivirina ni klinično pomembno.
English: Co-administration of EVOTAZ and rivaroxaban may result in increased exposure to rivaroxaban and may lead to increased bleeding.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ in rivaroksabana se lahko poveča izpostavljenost rivaroksabanu, kar lahko povzroči pogostejše krvavitve.
English: In clinical trials of antiretroviral treatment naive patients treated with unboosted atazanavir, the I50L substitution, sometimes in combination with an A71V change, is the signature resistance substitution for atazanavir.
Slovenian: Pri zdravljenju z atazanavirjem brez okrepitve farmakokinetike v kliničnih preskušanjih, izvedenih pri bolnikih, ki se predhodno še niso zdravili s protiretrovirusnimi zdravili, je bila substitucija I50L, včasih v kombinaciji s spremembo A71V, značilna rezistenčna substitucija proti atazanavirju.
English: The following statements reflect the preclinical safety results of the individual active substances of EVOTAZ.
Slovenian: V nadaljevanju navajamo predklinične podatke o varnosti, pridobljene s posameznima učinkovinama zdravila EVOTAZ.
English: EVOTAZ should not be used in combination with ritonavir or medicinal products containing ritonavir due to similar pharmacological effects of cobicistat and ritonavir on CYP3A (see section 4.5).
Slovenian: Zdravila EVOTAZ se ne sme uporabljati v kombinaciji z ritonavirjem ali zdravili, ki vsebujejo ritonavir, saj so farmakološki učinki kobicistata in ritonavirja na CYP3A podobni (glejte poglavje 4.5).
English: Glecaprevir AUC : ↑553% Glecaprevir Cmax : ↑306% (↑215% Glecaprevir Cmin : ↑1330% (↑885% Pibrentasvir AUC : ↑64% (↑48% Pibrentasvir Cmax : ↑29% (↑15% Pibrentasvir Cmin: ↑129% (↑95% Atazanavir AUC : ↑11% (↑3% Atazanavir Cmax : ↔ 0% (↓ Atazanavir Cmin: ↑16% (↑7% * Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported.
Slovenian: Glekaprevir AUC: ↑553% Glekaprevir Cmax: ↑306% (↑215% Glekaprevir Cmin : ↑1330% Pibrentasvir AUC: ↑64% (↑48% Pibrentasvir Cmax: ↑29% (↑15% Pibrentasvir Cmin: ↑129% (↑95% Atazanavir AUC: ↑11% (↑3% Atazanavir Cmax: ↔ 0% (↓ Atazanavir Cmin: ↑16% (↑7% * Poročali so o vplivu atazanavirja in ritonavirja na prvi odmerek glekaprevirja in pibrentasvirja.
English: Concentrations of these medicinal products may be increased when co-administered with EVOTAZ resulting in the potential for increased adverse events usually associated with these anticancer medicinal products.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ se koncentracije teh zdravil lahko povečajo, kar lahko poveča pojavnost neželenih učinkov, običajno povezanih z uporabo teh zdravil za zdravljenje rakavih bolezni.
English: In in vivo studies in rats, atazanavir did not induce micronuclei in bone marrow, DNA damage in duodenum (comet assay), or unscheduled DNA repair in liver at plasma and tissue concentrations exceeding those that were clastogenic in vitro.
Slovenian: V študijah in vivo pri podganah atazanavir ni povzročil nastanka mikrojeder v kostnem mozgu, poškodb DNA v dvanajstniku (kometni test) ali nepredvidenega popravila DNA v jetrih ob plazemskih in tkivnih koncentracijah, ki so presegale koncentracije, klastogene in vitro.
English: Moderate to severe hepatic impairment.
Slovenian: Zmerna do huda okvara jeter.
English: Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels.
Slovenian: Podatki o sočasni uporabi parenteralnega midazolama z drugimi zaviralci proteaz kažejo, da se plazemske koncentracije midazolama lahko povečajo za 3do 4-krat.
English: Higher concentrations could potentiate tenofovir-associated adverse reactions, including renal disorders.
Slovenian: Večje koncentracije lahko okrepijo neželene učinke tenofovirja, vključno z boleznimi ledvic.
English: When co-administering tenofovir alafenamide/emtricitabine and EVOTAZ, the recommended dose of tenofovir alafenamide/emtricitabine is 10/200 mg once daily.
Slovenian: Pri sočasni uporabi alafenamidtenofovirata/emtricitabina in zdravila EVOTAZ je priporočeni odmerek alafenamidtenofovirata/emtricitabina 10 mg/200 mg enkrat na dan.
English: The overall safety profile of EVOTAZ is based on available data from clinical trials conducted with atazanavir, atazanavir boosted with either cobicistat or ritonavir, and post-marketing data.
Slovenian: Celoten varnostni profil zdravila EVOTAZ temelji na podlagi razpoložljivih podatkov iz kliničnih preskušanj, izvedenih z atazanavirjem, atazanavirjem, okrepljenim s kobicistatom ali z ritonavirjem, in podatkov, pridobljenih med spremljanjem zdravil po prihodu na trg.
English: Atazanavir inhibits UGT and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities.
Slovenian: Atazanavir zavira UGT in lahko vpliva na presnovo irinotekana, pri čemer se lahko poveča toksičnost irinotekana.
English: The effect of EVOTAZ on fertility in humans has not been studied.
Slovenian: Vpliva zdravila EVOTAZ na plodnost pri človeku niso raziskovali.
English: Patients with co-existing conditions
Slovenian: Bolniki s sočasnimi boleznimi
English: Discuss with your doctor the precautions needed to avoid infecting other people.
Slovenian: O potrebnih previdnostnih ukrepih za preprečitev prenosa okužbe na druge se posvetujte z zdravnikom.
English: Atazanavir increased opacity of bovine corneas in an in vitro ocular irritation study, indicating it may be an ocular irritant upon direct contact with the eye.
Slovenian: Atazanavir je v in vitro študiji očesnega draženja povečal opalescenco goveje roženice, kar kaže, da bi ob neposrednem stiku z očesom lahko povzročil draženje.
English: If EVOTAZ is co-administered with irinotecan, patients should be closely monitored for adverse reactions related to irinotecan.
Slovenian: Če se zdravilo EVOTAZ uporablja skupaj z irinotekanom, je bolnika treba skrbno nadzirati glede pojava neželenih učinkov irinotekana.
English: However, a higher percentage of subjects in the atazanavir boosted with cobicistat group had increases in total bilirubin > 2 x ULN than those in the atazanavir boosted with ritonavir group (88.0% versus 80.9%).
Slovenian: Vendar pa je bil odstotek bolnikov z vrednostjo celokupnega bilirubina > 2 x ZMN v skupini, ki je prejemala atazanavir, okrepljen s kobicistatom, večji kot v skupini, ki je prejemala atazanavir, okrepljen z ritonavirjem (88,0 % v primerjavi z 80,9 %).
English: Pink, oval, biconvex, film-coated tablet of approximate dimensions of 19 mm x 10.4 mm, debossed with "3641" on one side and plain on the other side.
Slovenian: Rožnata, ovalna, obojestransko izbočena, filmsko obložena tableta, velika približno 19 mm x 10,4 mm, z oznako “3641” na eni in brez oznak na drugi strani.
English: Complex or unknown mechanisms of drug interaction preclude extrapolation of ritonavir drug interactions to certain cobicistat drug interactions.
Slovenian: Zaradi kompleksnega ali neznanega mehanizma interakcij med zdravili, ugotovljenih interakcij med ritonavirjem in drugimi zdravili ni mogoče preprosto prenesti na določene interakcije med kobicistatom in drugimi zdravili.
English: Co-administration of EVOTAZ and medicinal products that induce CYP3A4 is contraindicated or not recommended (see sections 4.3 and 4.5) because, in addition to decreased plasma concentrations of atazanavir due to induction of CYP3A4, decreased plasma concentrations of cobicistat could result in cobicistat plasma levels that are insufficient to achieve adequate pharmacoenhancement of atazanavir.
Slovenian: Sočasna uporaba zdravila EVOTAZ in zdravil, ki inducirajo CYP3A4, je kontraindicirana ali pa ni priporočljiva (glejte poglavji 4.3 in 4.5), saj se poleg zmanjšanja koncentracij atazanavirja v plazmi zaradi indukcije CYP3A4 lahko zmanjšajo tudi koncentracije kobicistata v plazmi, kar lahko povzroči takšne vrednosti kobicistata v plazmi, ki več ne zadostujejo za zagotavljanje ustrezne okrepitve farmakokinetike atazanavirja.
English: Disopyramide Flecainide Mexiletine Propafenone
Slovenian: Dizopiramid Flekainid Meksiletin Propafenon
English: The following statements reflect the pharmacokinetic properties of atazanavir in combination with cobicistat or the individual components of EVOTAZ.
Slovenian: V nadaljevanju navedene farmakokinetične lastnosti se nanašajo na atazanavir v kombinaciji s kobicistatom ali posamezne sestavine zdravila EVOTAZ.
English: In a 3-month combination oral toxicity study of atazanavir and cobicistat in rats, there were no toxicologic interactions apparent as no additive or synergistic toxicities were observed.
Slovenian: V 3-mesečni študiji toksičnosti peroralne uporabe atazanavirja in kobicistata pri podganah niso ugotovili toksikoloških interakcij, prav tako pa tudi niso opazili aditivnih ali sinergističnih toksičnih učinkov.
English: Clarithromycin Cmax ↑50% (↑32%
Slovenian: Klaritromicin Cmax ↑50% (↑32%
English: The most frequently reported laboratory abnormality in patients receiving regimens containing atazanavir and one or more NRTIs was elevated total bilirubin reported predominantly as elevated indirect [unconjugated] bilirubin (87% Grade 1, 2, 3, or 4).
Slovenian: Najpogostejše laboratorijsko ugotovljene nepravilnosti pri bolnikih, zdravljenih s shemami, ki so vključevale atazanavir in enega ali več NRTI-jev, je bilo zvišanje vrednosti celokupnega bilirubina, predvsem zvišanje vrednosti indirektnega [nekonjugiranega] bilirubina (87 %, stopnja 1, 2, 3 ali 4).
English: Periodic safety update reports
Slovenian: Redno posodobljena poročila o varnosti zdravila (PSUR)
English: Carbamazepine Phenobarbital Phenytoin
Slovenian: Karbamazepin Fenobarbital Fenitoin
English: During in vitro studies, cloned human cardiac potassium channel (hERG), was inhibited by 15% at a concentration (30 μM) of atazanavir corresponding to 30 fold the free drug concentration at Cmax in humans.
Slovenian: Med študijami in vitro je prišlo do 15-odstotnega zavrtja kloniranih človeških srčnih kalijevih kanalčkov (hERG), in sicer pri koncentraciji atazanavirja (30 μM), kar ustreza 30-kratni koncentraciji proste učinkovine pri Cmax pri človeku.
English: Swallow the tablet whole; do not crush or chew the tablets.
Slovenian: Tablet ne smete drobiti ali žvečiti.
English: It is important to tell your doctor if you are taking: Corticosteroids including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone.
Slovenian: Pomembno je, da zdravnika obvestite tudi, če jemljete kortikosteroide, vključno z betametazonom, budezonidom, flutikazonom, mometazonom, prednizonom, triamcinolonom.
English: There is a risk of loss of therapeutic effect and development of resistance to atazanavir (see section 4.3).
Slovenian: Obstaja tveganje za izgubo terapevtskega učinka in razvoj odpornosti proti atazanavirju (glejte poglavje 4.3).
English: Consideration should be given to official guidance on the appropriate treatment of tuberculosis in HIV infected patients.
Slovenian: Pri bolnikih, okuženih z virusom HIV, je treba upoštevati uradne smernice za ustrezno zdravljenje tuberkuloze.
English: *Lack of pharmacokinetics interaction bounds 70-143%
Slovenian: *Pomanjkanje mej farmakokinetičnih interakcij 70
English: Given that cobicistat has been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co-administered with EVOTAZ.
Slovenian: Glede na to, da je bilo dokazano, da kobicistat nima pomembnega vpliva na koncentracije metadona, interakcij pri sočasni uporabi metadona in zdravila EVOTAZ ne pričakujemo.
English: Some examples include, but are not limited to etravirine, nevirapine, efavirenz, boceprevir, fluticasone and bosentan (see Table 1).
Slovenian: Takšna zdravila so med drugimi etravirin, nevirapin, efavirenz, boceprevir, flutikazon in bosentan (glejte tabelo 1).
English: Dose titration of the calcium channel blockers should be considered.
Slovenian: Razmisliti je treba o titraciji odmerka zaviralcev kalcijevih kanalčkov.
English: 14-OH clarithromycin 14-OH clarithromycin AUC ↓70%
Slovenian: 14-OH klaritromicin 14-OH klaritromicin AUC ↓70%
English: Psychiatric disorders common insomnia, abnormal dreams uncommon depression, sleep disorder, disorientation, anxiety
Slovenian: Psihiatrične motnje pogosti nespečnost, nenormalne sanje občasni depresija, motnje spanja, dezorientiranost, tesnoba
English: Particular caution should be used when prescribing PDE5-inhibitors (sildenafil, tadalafil, vardenafil, or avanafil) for the treatment of erectile dysfunction in patients receiving EVOTAZ.
Slovenian: Pri bolnikih, ki se zdravijo z zdravilom EVOTAZ, je potrebna posebna previdnost pri predpisovanju zaviralcev PDE5 (sildenafil, tadalafil, vardenafil ali avanafil) za zdravljenje erektilne disfunkcije.